Lytix Biopharma AS (DE:6BG) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Lytix Biopharma has announced promising preliminary results for their cancer treatment LTX-315, showing significant efficacy in treating basal cell carcinoma (BCC). The treatment demonstrated complete tumor elimination in 51% of cases and presents a potential non-surgical alternative for millions of BCC patients. This development highlights a substantial commercial opportunity in the fast-growing skin cancer market.
For further insights into DE:6BG stock, check out TipRanks’ Stock Analysis page.
